Research
Study index
Every study PepIndex has recorded, stored once and referenced from wherever it is relevant. Each carries its evidence type, the model it used, its sample size where reported, and what it found — including null results, which are recorded rather than quietly dropped. Each has a permalink, so a study can be cited without being retyped.
- Studies indexed
- 102
- Human evidence
- 97
- Preclinical only
- 5
| Study | Evidence type | Compounds | Model | n | What it reported | Source |
|---|---|---|---|---|---|---|
| Meta-analyses of GLP-1 receptor agonist trialsPubMed listing | Meta-analysis | Semaglutide, Tirzepatide | Not recorded | — | Placeholder seed record. Pooled analyses of trials of approved GLP-1 receptor agonist products. Meta-analytic findings inherit the population and product of the trials they pool, and do not transfer to material obtained outside that supply chain. | Listing |
| Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysisBMJ (Clinical research ed.) · 2024 | Meta-analysis | Cagrilintide | Not recorded | — | To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Systematic review and network meta-analysis. PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and… | PMID 38286487 |
| Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trialsThe Australian and New Zealand journal of psychiatry · 2021 | Meta-analysis | Glutathione | Not recorded | — | Currently, pharmaceutical treatment options for autism spectrum disorder are limited. Brain glutaminergic dysregulation is observed in autism spectrum disorder. N-acetylcysteine, which can be converted to glutathione and subsequently release glutamate into the extracellular space, and thus reduce glutamatergic neurotransmission at synapses, is considered a potential drug for autism spectrum disorder treatment. Here, we analyzed the treatment effects of N-acetylcysteine on aut… | PMID 32900213 |
| Serum kisspeptin levels in polycystic ovary syndrome: A meta-analysisThe journal of obstetrics and gynaecology research · 2021 | Meta-analysis | Kisspeptin | Not recorded | — | To clarify the association of serum kisspeptin levels in women with polycystic ovary syndrome (PCOS) by meta-analysis. Two English databases and two Chinese databases were searched for the relationship between kisspeptin and PCOS published from 2009. After the studies screening according to specific principles, we used STATA 12.0 for meta-analysis. Standardized mean difference (SMD) and its 95% confidence intervals (95% CIs) were used as the effect size and STATA 12.0 softwar… | PMID 33765692 |
| Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in WomenJournal of sex research · 2021 | Meta-analysis | PT-141 | Not recorded | — | Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women. 72.72% of protocol-listed outcomes were not reported by Kingsberg et al., who provided results of 15 secondary measures which were not listed in the study protocols. None of their efficacy outcomes were reported in line with CONSORT data reporting standards and no secondary outcome had a stated rationale or cited evidence of val… | PMID 33678061 |
| Female Sexual Dysfunction and the Placebo Effect: A Meta-analysisObstetrics and gynecology · 2018 | Meta-analysis | PT-141 | Not recorded | — | To quantify the placebo effect of various pharmacologic modalities including neuromodulators, hormonal agents, and onabotulinum toxin A for female sexual dysfunction. Using Meta-analyses Of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, ClinicalTrials.gov, and the Cochrane Review databases. Eleven search terms, "female sexual dysfunction" "treatment" in combination with "hypoactive sexual desire," "arousal disorder," "sex… | PMID 29995725 |
| Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trialsMetabolism: clinical and experimental · 2024 | Meta-analysis | Retatrutide | Not recorded | — | This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis. Relevant randomized controlled trials (RCTs) with an intervention duration of at least 16 weeks assessing seven GLP-1 receptor agonists and polyagonists (mazdutide, 6 or 4.5 mg; retatrutide, 12 or 8 mg; tir… | PMID 39305981 |
| Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trialsObesity research & clinical practice · 2026 | Meta-analysis | Tesamorelin | Not recorded | — | HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormone-releasing hormone analogue, that has been proposed as a targeted therapy. We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorel… | PMID 41545261 |
| Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trialsFrontiers in cellular and infection microbiology · 2025 | Meta-analysis | Thymosin Alpha-1 | Not recorded | — | Despite advances in understanding sepsis pathophysiology and extensive research, few treatments effectively target its underlying immune dysfunction. Thymosin α1 (Tα1) shows promise as an immunomodulator, but its impact on sepsis remains unclear. A search strategy was designed to include any prospective clinical studies using Tα1 for assessing 28-day mortality in patients with sepsis, excluding combination therapy studies. We conducted trial sequential analy… | PMID 40969554 |